Complexity of Blocking Bivalent Protein–Protein Interactions: Development of a Highly Potent Inhibitor of the Menin–Mixed-Lineage Leukemia Interaction
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The protein–protein interaction between menin and mixed-lineage leukemia 1 (MLL1) plays an important role in development of acute leukemia with translocations of the MLL1 gene and in solid tumors. Here, we report the development of a new generation of menin–MLL1 inhibitors identified by structure-based optimization of the thienopyrimidine class of compounds. This work resulted in compound 28 ( MI-1481 ), which showed very potent inhibition of the menin–MLL1 interaction (IC 50 = 3.6 nM), representing the most potent reversible menin–MLL1 inhibitor reported to date. The crystal structure of the menin- 28 complex revealed a hydrogen bond with Glu366 and hydrophobic interactions, which contributed to strong inhibitory activity of 28 . Compound 28 also demonstrates pronounced activity in MLL leukemia cells and in vivo in MLL leukemia models. Thus, 28 is a valuable menin–MLL1 inhibitor that can be used for potential therapeutic applications and in further studies regarding the role of menin in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of α-helix-mediated protein–protein interactions using designed molecules
Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727
Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation
Funato, K., Major, T., Lewis, P. W., Allis, C. D., & Tabar, V. (2014) · Science · doi:10.1126/science.1253799 · Cited by 390
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312 · cited 3×
“Furthermore, compounds 24-27 demonstrate good microsomal stability, with the sulfonyl (26) or sulfonamide (27) analogues exhibiting the longest half-life in mouse liver microsomes (T1/2 > 60 min).”
BackgroundMethodArkin, M. R., & Whitty, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.125 · Cited by 190
Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133 · cited 2×
“4-methyl-1-(2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)-5-((4-((6-(2,2,2trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1Hindole-2-carbonitrile (19)—The reaction was performed with the methanesulfonyl chloride.”
MethodHe, S., Senter, T. J., Pollock, J., Han, C., Upadhyay, S. K., Purohit, T., Gogliotti, R. D., Lindsley, C. W., Cierpicki, T., Stauffer, S. R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401868d · Cited by 99 · cited 2×
“General procedure for synthesis of compounds (11, 12, 17)—Compound 3 (20 mg, 0.”
MethodSelf-citationCierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Self-citation
Cited by
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules
Henley, M. J., & Koehler, A. N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00199-0 · Cited by 409
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
Klossowski, S., Miao, H., Kempinska, K., Wu, T., Purohit, T., Kim, E., Linhares, B. M., Chen, D., Jih, G., Perkey, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129126 · Cited by 246
“The menin-MLL1 inhibitors that we developed previously, including MI-503 (17) and MI-1481 (21), demonstrate relatively robust activity and an on-target mechanism of action in the MLL-rearranged leukemic cells and delay leukemia progression in mouse models of MLL leukemia.”
InfluentialSelf-citationBiolayer interferometry and its applications in drug discovery and development
Jug, A., Bratkovič, T., & Ilaš, J. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117741 · Cited by 107
Aguilar, A., Zheng, K., Xu, T., Xu, S., Huang, L., Fernandez-Salas, E., Liu, L., Bernard, D., Harvey, K. P., Foster, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00021 · Cited by 39
“4-Cyclopentyl-4-(1-((1-(4-(pyridin-4-ylsulfonyl)phenyl)azetidin-3yl)methyl)piperidin-4-yl)-1,2,3,4-tetrahydroisoquinoline (22): Compound 90 (20 mg, 0.”
Metadata
- Authors
- Borkin, D., Klossowski, S., Pollock, J., Miao, H., Linhares, B. M., Kempinska, K., Jin, Z., Purohit, T., Wen, B., He, M., Sun, D., Cierpicki, T., & Grembecka, J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-05-08
- Volume
- 61
- Issue
- 11
- Pages
- 4832-4850
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2799870037
- Cited by
- 63
- References
- 7
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complexity of Blocking Bivalent Protein–Protein Interactions: Development of a Highly Potent Inhibitor of the Menin–Mixed-Lineage Leukemia Interaction. https://app.cochat.ai/papers/10.1021/acs.jmedchem.8b00071
- The paper
- Borkin, D., Klossowski, S., Pollock, J., Miao, H., Linhares, B. M., Kempinska, K., Jin, Z., Purohit, T., Wen, B., He, M., Sun, D., Cierpicki, T., & Grembecka, J. (2018). Complexity of Blocking Bivalent Protein–Protein Interactions: Development of a Highly Potent Inhibitor of the Menin–Mixed-Lineage Leukemia Interaction. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b00071
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.